22 jun: Belgium June Business Confidence -13.2 Vs -11.2 In May
22 jun: Brazil Government Will Cut Fuel Tax To Help Petrobras -Report
22-06-2012 15:35:00

EMA Recommends Against Marketing Authorization to Pfizer and Protalix for Gaucher Treatment

Relateret indhold
Relateret debat
28 jan - 
Pfizer har en kæmpe pengetank for øjeblikket på 33 mia ..
22 dec - 
I consider this really is an informative post and it ca..

By Saabira Chaudhuri

The European Medicines Agency has recommended against marketing authorization for Pfizer Inc. (PFE) and Protalix BioTherapeutics Inc. (PLX) for their Gaucher disease treatment, taliglucerase alfa.

Protalix's shares were down 12% premarket to $5.83. The stock is up 34% year-to-date. Pfizer's shares were flat premarket at $22.60. The stock is up 4% year-to-date.

The European agency made a positive risk-benefit assessment, concluding that the benefits of the treatment outweighed its risks, but didn't recommend marketing authorization because Shire PLC's (SHPGY, SHP.LN) velaglucerase alfa has received prior marketing authorization with an orphan drug designation for the same condition. Shire's treatment has marketing exclusivity in the European Union for 10 years from August 2010, the time of authorization.

"While we are disappointed by the CHMP's [EMA's Committee for Medicinal Products for Human Use] recommendation, we are encouraged that the committee gave a positive risk-benefit assessment. The recommendation was based solely on orphan market exclusivity and not the safety and efficacy profile of taliglucerase alfa," said General Manager Diem Nguyen of Pfizer's Biosimilars division. "Pfizer will continue to work with relevant stakeholders to determine appropriate next steps."

Pfizer and Protalix BioTherapeutics entered into an agreement to develop and commercialize taliglucerase alfa, an enzyme replacement therapy, in November 2009. The treatment was approved by the Food and Drug Administration last month for the long term enzyme replacement therapy of adults with a confirmed diagnosis of Type 1 Gaucher disease.

According to the National Institute of Health's National Institute of Neurological Disorders and Stroke, Gaucher disease is the most common of the inherited metabolic disorder known as lipid storage diseases. Lipids are fatty materials that include oils, fatty acids, waxes, and steroids [such as cholesterol and estrogen]. Gaucher disease is caused by a deficiency of the enzyme glucocerebrosidase. Fatty materials can accumulate in the spleen, liver, lungs, bone marrow, and brain. Symptoms may include skeletal disorders, enlarged spleen and liver, liver malfunction, anemia, and yellow spots in the eyes.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

(END) Dow Jones Newswires

June 22, 2012 09:35 ET (13:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Danske Bank udnævner Gilbert Kohnke til kreditchef - NY

30-01-2015 15:50:19
Danske Bank har udnævnt Gilbert Kohnke til Chief Risk Officer (CRO). Han får ansvar for Group Risk Management og indtræder i bankens direktion med virkning fra ..

Mærsk: Japansk treenighed tegner et blandet rate-billede

30-01-2015 12:02:51
De tre japanske rederier MOL, NYK og K-Line har offentliggjort 3. kvartalsregnskaber for deres forskudte regnskabsår 2014/15. De tre rederier er alle repræsente..

Aktier/åbning: Aktierne er i plus i C20 - kun TDC står til fald

30-01-2015 09:30:05
Det danske aktiemarked fejrer weekendens komme med stigninger næsten over hele linjen. Kun TDC ligger i rødt i bunden af C20 Cap-indekset med et fald på 0,14 pc..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Pfizer Inc 31,25 -1,8% Fald i aktiekurs
Shire ORD 5P 4.888,67 -0,2% Fald i aktiekurs
Pfizer Inc 260,00 -0,4% Fald i aktiekurs
Pfizer Incorporated COM .. 31,63 0,1% Stigning i aktiekurs
Pfizer 29,65 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen
Køb

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
31. januar 2015 23:35:58
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150130.2 - EUROWEB2 - 2015-01-31 23:35:58 - 2015-01-31 23:35:58 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x